Acute kidney injury (AKI) is a clinical scenario in which there is sudden loss of renal function. The term AKI recently has replaced “acute renal failure” (ARF), which was first described by William Heberden in 1802 as “ischuria renalis” [1,2]. It is characterized by oliguria and rapid development of azotemia [3]. This clinical entity usually is initiated and caused by hypovolemia and/or hypotension and frequently is associated with multiorgan failure [4]. In the United States, numerous studies have focused on analysis of data from the International Classification of Disease coding to measure the incidence of AKI in different clinical settings, with results showing increased incidence over time. The "Kidney Disease: Improving Global Outcomes" (KDIGO)-based criteria used to analyze the epidemiology of AKI might yield a much higher estimated incidence of AKI than the code-classified criteria [5,6]. Due to the absence of standardized classification criteria for AKI, there are many variations in the reported incidence and prevalence rates among hospitalized patients, ranging from < 1% to 66% [7].

Different etiologies contribute to the development of AKI, mainly leading to a rapid decline in glomerular filtration rate. Those include a decrease in renal blood flow in the case of prerenal AKI [4] or other causes in the settings of intrinsic renal or postrenal AKI. The kidneys are most vulnerable to hypoperfusion when autoregulation is impaired. This is seen frequently in elderly patients; patients with atherosclerosis, hypertension, diabetes, or early chronic kidney disease, where arterial and arteriolar...
Since necrosis is not evident always, there have been calls to substitute the term “acute tubular injury” (ATI).

The morphologic changes seen in ATI vary according to the severity of tubular damage. Mild changes include tubular dilation, loss of the proximal tubular brush border, and apical blebbing, particularly in the S3 segment of the proximal tubule. Indeed, the proximal tubule is the most susceptible site to injury [11]. The severe forms of ATI manifest from individual cells to confluent necrosis. Detachment from the basement membrane and shedding of proximal tubular epithelial cells with luminal confluent necrosis. Detachment from the basement membrane and shedding of proximal tubular epithelial cells with luminal accumulation of necrotic debris in distal tubular segments are characteristic of this entity [4,12]. However, renal tubules have a remarkable capacity to regenerate lost cells, usually within less than a week [13]. It is suggested in the literature that restoration of lost renal tubular cells is secondary to regeneration of the tubular epithelium [14]. Histopathological analysis of the kidney tissue distinguishes four stages of the renal tubular regeneration (RTR) process [15]. In the first stage, there is inflammation and death of the tubular epithelium via apoptosis, necrosis, or other death mechanisms. In the second stage, tubular epithelial cells undergo changes, such as a loss of brush border, tubular flattening, and rapid loss of cell polarity [16,17]. In this stage, cells change from the epithelial to mesenchymal phenotype in a process known as epithelial-to-mesenchymal transition (EMT) and overexpress vimentin (VIM) [18,19]. Regenerating cells are characterized by cytoplasmic basophilia, karyomegaly, and nuclear crowding along the affected tubule segment [20]. In the third stage, enhanced proliferation of most kidney cells occurs through increased levels of growth factors, including insulin like growth factor 1, hepatocyte growth factor, and fibroblast growth factors [21]. Lastly, maturation of epithelial cells occurs with restoration of nephron function [22].

The regenerative features of AKI/ATI are difficult to appreciate on routine light microscopy. The present study expands the assessment of the regenerative capacity of renal tubules in patients with AKI/ATI. We correlated the expression of VIM, a marker of RTR, with clinical and morphologic variables in individuals with varying degrees of AKI. Our results indicate that VIM expression is observed consistently in both AKI and chronic kidney disease (CKD). However, VIM labeling, in areas devoid of fibrosis and other signs of chronic damage, can serve as an immunohistochemical (IHC) biomarker to estimate AKI-associated regenerative responses in autopsies and potentially in surgical biopsies.

MATERIALS AND METHODS

Study design and setting

We conducted a retrospective 10-year review (2010–2020) of all adult autopsies performed at Mount Sinai Medical Center of Florida, with cause of death related to hypoperfusion. Exclusion criteria were (1) death related to trauma, (2) death during surgery, and (3) complete autolysis of kidney tissues. Clinicopathological parameters of the patients were retrieved from electronic pathology and medical records. The variables collected were age, gender, cause of death (cardiac, respiratory, stroke, sepsis, among others), CKD, CKD stage, fold estimated glomerular filtration rate (eGFR), fold creatinine, chronic hemodialysis, diabetes mellitus, hypertension, shock during hospitalization, clinical evidence of AKI/ATI, AKI type, arteriosclerosis, arteriolosclerosis, arteriolosclerosis severity, glomerulosclerosis, glomerulosclerosis severity, significant interstitial fibrosis, interstitial fibrosis severity, tubular atrophy, tubular atrophy severity, pathologic evidence of AKI, tubulorrhexis, pathologic evidence of ATN, evidence of regenerating tubular epithelium, and renal peritubular microenvironment features on hematoxylin and eosin (H&E) stains (cortical) and on periodic acid–Schiff (PAS) stains (cortical).

Histopathologic evaluation

Tissue samples were fixed in neutral buffered formalin and embedded in paraffin for histologic processing. Slides of the kidney sections were stained with H&E and PAS reaction and evaluated in a blinded fashion by two independent pathologists with experience in renal pathology. No significant interobserver disagreement was noted in the interpretation between the two pathologists. Although no quantitative criteria were used to assess AKI and RTR, AKI was defined by the presence of tubular dilation, loss of the proximal tubular brush border, tubulorrhexis, and apical blebbing [4], and RTR was defined by cytoplasmic basophilia, karyomegaly, and nuclear crowding along the affected tubule segment [20]. The collective presence of those features was necessary to define AKI and RTR and was achieved by assessing tissue slides systematically and observing renal tubules within at least 10 high power fields (HPFs). Arteriosclerosis was described as thickening of the intima or media of the arteries. Arteriolosclerosis was characterized by hyalinosis of the afferent or efferent vessels and arterioles [23]. Chronic damage was

https://jpatholtm.org/
Vimentin expression in AKI  •  371

estimated by evaluating tissue fibrosis including glomerulosclerosis [24], interstitial fibrosis, and tubular atrophy, defined as reduced size of tubules with attenuation of the luminal epithelium [25]. Autolysis was characterized by ghost cells with pyknotic or absent nuclei [26]. Fragmentation/duplication of the basement membrane and thickened basement membrane were recorded.

IHC staining for VIM (Ventana Medical Systems Inc., Tucson, AZ, USA) protein expression was performed using standard processing techniques. Appropriate positive and negative controls were run simultaneously. VIM expression was assessed by positive gold-brown cytoplasmic stain only in the tubular cells. Screening of the kidney tissue sections was performed in a systematic manner. In areas without chronic changes or acute tubulointerstitial inflammation, an average of approximately 30 tubules was counted randomly within 10 HPFs. Scoring was performed at 400x magnification. In non-pathological conditions, glomeruli normally stain positive for VIM [27], serving as internal positive controls in our study. A positive tubule was defined as immunoreactivity of more than 50% of the tubular epithelial cells. The percentage of VIM expression was calculated by dividing the number of tubules with ≥50% VIM-positive cells by the total number of tubules (approximately 30), multiplied by 100. This percentage is referred to as the VIM score. We defined our VIM positivity threshold by setting a cutoff of 3% (Fig. 1B). Evaluation was restricted to areas without advanced/obvious acute or chronic changes as VIM is expressed ubiquitously in tubular atrophy and areas of severe fibrosis. In fact, persistence of VIM+ epithelial cells in CKD likely is responsible for activating fibrogenic pathways, that is, those not part of RTR.

Statistical analysis

The VIM score was categorized into less than 3% and greater than or equal to 3%. This cutoff of 3% was assigned based on the VIM score distribution, where 95.7% of the total population (22/23) clustered in the “less than or equal to 20% VIM score.” Multiple cutoffs have been explored to determine the optimal stratification of patients. The optimal cutoff point for VIM that provided the greatest statistical significance was 3%. Data retrieved from medical charts were entered into a Microsoft Excel spreadsheet that was designed specifically for this study. Then, the data were transferred into the Statistical Package of Social Science (IBM Corp., Released 2013, SPSS Statistics for Windows ver. 22.0, Armonk, NY, USA), which was used for data cleaning, management, and analyses. Descriptive statistics were carried

| CKD (diffuse strong VIM expression) | AKI |
|-----------------------------------|-----|
| Tubular atrophy                   | Low VIM (<3%) |
| Tubular thyroidization            | High VIM (≥3%) |

*Fig. 1.* Representative hematoxylin and eosin (H&E) (upper panels) and immunohistochemistry (lower panels) images of kidney tissues. (A) Kidney tissues showing diffuse and strong vimentin (VIM) expression in areas of chronic tubular damage (patients with chronic kidney disease). (B) Kidney tissues showing low and high VIM expression. Slides were stained with H&E and VIM stains, and images were examined at ×400.
out and reported as frequencies and percentages for categorical variables and as means ± standard deviations for continuous variables. Characteristics of patients and other clinicopathological parameters among the two studied groups (VIM < 3%, low, and ≥ 3%, high) were tabulated. Baseline comparisons between the two studied groups were performed using the Mann-Whitney U test for continuous variables. The chi-square test was used to assess any significant association between the categorical variables. Thereafter, univariate logistic regression was used to determine the associations between VIM (low/high) as a dependent variable and other clinicopathological parameters as independent variables. The level of significance was set at p < .05 for all statistical analyses.

RESULTS

VIM expression and its correlation with clinical characteristics

A total of 23 patients was selected based on the inclusion criteria. From this group, high VIM expression (≥ 3%) was observed in 16 patients (Fig. 2). Among our patient cohort, 13 (56.5%) were females and 10 (43.5%) were males. Patients were divided into two age groups, ≤ 65 years (7 patients, 30.4%) and > 65 years (16 patients, 69.6%). The patients were distributed according to cause of death: cardiac (4 patients, 17.4%), respiratory (6 patients, 26.1%), stroke (2 patients, 8.7%), sepsis (7 patients, 30.4%), and other (3 patients, 13.0%). There were 16 patients (69.6%) with no CKD and seven patients (30.4%) with CKD. Fold eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation [28]. Also, fold creatinine was estimated using the lowest value recorded during or before hospitalization and the highest value recorded during hospitalization. Chronic hemodialysis was found in one patient (4.3%). Sixteen patients (69.6%) did not have diabetes mellitus, and 16 patients (69.6%) had hypertension. Shock during hospitalization was present in 10 patients (43.5%). Clinical evidence of acute kidney injury was documented in 13 patients (56.5%) (Table 1). No statistically significant difference was found between patients regarding age, gender, cause of death, CKD, CKD stage, chronic hemodialysis, diabetes mellitus, hypertension, shock during hospitalization, fold eGFR, fold creatinine, or clinical evidence of acute kidney injury with respect to VIM expression.

VIM expression is significantly correlated with AKI and RTR

We next sought to assess the correlation between VIM expression and other histopathologic variables. High VIM expression was significantly associated with arteriosclerosis, arteriosclerosis severity, and glomerulosclerosis (p = .005, p = .002, and p = .033, respectively) (Table 1). Kidney tissues with pathologic evidence of ATN and RTR had significantly higher VIM expression (p = .036 and p = .007, respectively) (Table 1, Fig. 2). Also, renal peritubular microenvironment features showing regenerative changes on H&E were associated with high VIM expression (p = .009) (Table 1). In univariate models, kidney tissues with evidence of AKI and RTR were 15.00-fold more likely to have high VIM expression (odds ratio [OR], 7.500; 95% confidence interval [CI],

![Graph](https://patholtm.org/)
### Table 1. Correlation between vimentin expression and acute kidney injury

| Variable                  | Total       | Vimentin expression | p-value |
|---------------------------|-------------|---------------------|---------|
|                           | Low < 3%    | High ≥ 3%           |         |
| Age (mean ± SD)           | 69.00 ± 15.03 | 57.86 ± 15.96      | .015    |
| Age (yr)                  |             |                     | .066    |
| ≤ 65                      | 7 (30.4)    | 4 (57.1)            | 3 (42.9) |
| > 65                      | 16 (69.6)   | 3 (18.8)            | 13 (81.3) |
| Sex                       |             |                     | .382    |
| Female                    | 13 (56.5)   | 3 (23.1)            | 10 (76.9) |
| Male                      | 10 (43.5)   | 4 (40.0)            | 6 (60.0) |
| Cause of death            |             |                     | .777    |
| Cardiac                   | 4 (17.4)    | 1 (25.0)            | 3 (75.0) |
| Respiratory               | 6 (26.1)    | 2 (33.3)            | 4 (66.7) |
| Stroke                    | 2 (8.7)     | 1 (50.0)            | 1 (50.0) |
| Sepsis                    | 7 (30.4)    | 2 (28.6)            | 5 (71.4) |
| Other                     | 3 (13.0)    | 0                   | 3 (100)  |
| CKD                       |             |                     | .266    |
| No                        | 16 (69.6)   | 6 (37.5)            | 10 (62.5) |
| Yes                       | 7 (30.4)    | 1 (14.3)            | 6 (85.7) |
| CKD stage                 |             |                     | .792    |
| 1                         | -           | -                   | -       |
| 2                         | 1 (14.3)    | 0                   | 1 (100)  |
| 3                         | 5 (71.4)    | 1 (20.0)            | 4 (80.0) |
| 4                         | 1 (14.3)    | 0                   | 1 (100)  |
| 5                         | -           | -                   | -       |
| Fold eGFR                 |             |                     | .952    |
| < –0.5                    | 7 (38.9)    | 2 (28.6)            | 5 (71.4) |
| ≥ –0.5                    | 11 (61.1)   | 3 (27.3)            | 8 (72.7) |
| Fold creatinine           |             |                     | .457    |
| < 2.0                     | 12 (66.7)   | 4 (33.3)            | 8 (66.7) |
| ≥ 2.0                     | 6 (33.3)    | 1 (16.7)            | 5 (83.3) |
| Chronic hemodialysis      |             |                     | .499    |
| No                        | 22 (95.7)   | 7 (31.8)            | 15 (68.2) |
| Yes                       | 1 (4.3)     | 0 (0.0)             | 1 (100)  |
| Diabetes mellitus         |             |                     | .266    |
| No                        | 16 (69.6)   | 6 (37.5)            | 10 (62.5) |
| Yes                       | 7 (30.4)    | 1 (14.3)            | 6 (85.7) |
| Hypertension              |             |                     | .898    |
| No                        | 7 (30.4)    | 2 (28.6)            | 5 (71.4) |
| Yes                       | 16 (69.6)   | 5 (31.3)            | 11 (68.8) |
| Shock during hospitalization |           |                     | .968    |
| No                        | 13 (56.5)   | 4 (30.8)            | 9 (69.2) |
| Yes                       | 10 (43.5)   | 3 (30.0)            | 7 (70.0) |
| Clinical evidence of AKI  |             |                     | .493    |
| No                        | 9 (39.1)    | 2 (22.2)            | 7 (77.8) |
| Yes                       | 14 (60.9)   | 5 (35.7)            | 9 (64.3) |
| AKI type                  |             |                     | .603    |
| No                        | 9 (39.1)    | 2 (22.2)            | 7 (77.8) |
| Prerenal                  | 10 (43.5)   | 3 (30.0)            | 7 (70.0) |
| Renal                     | 4 (17.4)    | 2 (50.0)            | 2 (50.0) |
| Arteriosclerosis          |             |                     | .005    |
| No                        | 3 (13.0)    | 3 (100.0)           | 0       |
| Yes                       | 20 (87.0)   | 4 (20.0)            | 16 (80.0) |

(Continued to the next page)
### Table 1. Continued

| Variable                                                                 | Total No. of patients | Vimentin expression | p-value |
|-------------------------------------------------------------------------|-----------------------|---------------------|---------|
|                                                                         |                       | Low < 3% | High ≥ 3% |
| Arteriosclerosis                                                        |                       |          |          |
| No                                                                      | 13 (56.5)             | 6 (46.2) | 7 (53.8) |
| Yes                                                                     | 10 (43.5)             | 1 (10.0) | 9 (90.0) |
| Arteriosclerosis severity                                               |                       |          |          |
| Intimal thickening < media thickness                                    | 12 (52.2)             | 7 (58.3) | 5 (41.7) |
| Intimal thickening ≥ media thickness                                    | 11 (47.8)             | 0        | 11 (100) |
| Glomerulosclerosis                                                      |                       |          |          |
| <10% globally sclerotic glomeruli                                       | 12 (52.2)             | 6 (50.0) | 6 (50.0) |
| ≥10% globally sclerotic glomeruli                                      | 11 (47.8)             | 1 (9.1)  | 10 (90.9) |
| Glomerulosclerosis severity (%)                                         |                       |          |          |
| <10                                                                     | 17 (73.9)             | 6 (35.3) | 11 (64.7) |
| 10–50                                                                   | 4 (17.4)              | 1 (25.0) | 3 (75.0) |
| >50                                                                     | 2 (8.7)               | 0        | 2 (100)  |
| Significant interstitial fibrosis                                       |                       |          |          |
| No                                                                      | 7 (30.4)              | 4 (57.1) | 3 (42.9) |
| Yes                                                                     | 16 (69.6)             | 3 (18.8) | 13 (81.3) |
| Interstitial fibrosis severity (%)                                      |                       |          |          |
| <10                                                                     | 18 (78.3)             | 7 (38.9) | 11 (61.1) |
| 10–50                                                                   | 4 (17.4)              | 1 (25.0) | 3 (75.0) |
| >50                                                                     | 1 (4.3)               | 0        | 1 (100)  |
| Tubular atrophy (%)                                                     |                       |          |          |
| <10                                                                     | 21 (91.3)             | 7 (33.3) | 14 (66.7) |
| ≥10                                                                     | 2 (8.7)               | 0        | 2 (100)  |
| Tubular atrophy severity (%)                                            |                       |          |          |
| <10                                                                     | 21 (91.1)             | 7 (33.3) | 14 (66.7) |
| 10–50                                                                   | 1 (4.3)               | 0        | 1 (100)  |
| >50                                                                     | 1 (4.3)               | 0        | 1 (100)  |
| Pathologic evidence of AKI                                              |                       |          |          |
| No                                                                      | 9 (39.1)              | 5 (55.6) | 4 (44.4) |
| Yes                                                                     | 14 (60.9)             | 2 (14.3) | 12 (85.7) |
| Pathologic evidence of ATN                                              |                       |          |          |
| No                                                                      | 17 (73.9)             | 4 (23.5) | 13 (76.5) |
| Yes                                                                     | 6 (26.1)              | 3 (50.0) | 3 (50.0) |
| Evidence of regenerating tubular epithelium                             |                       |          |          |
| No                                                                      | 12 (52.2)             | 5 (41.7) | 7 (58.3) |
| Yes                                                                     | 11 (47.8)             | 2 (18.2) | 9 (81.8) |
| Renal peritubular microenvironment features on H&E (cortical)           |                       |          |          |
| No changes                                                              | 15 (65.2)             | 6 (40.0) | 9 (60.0) |
| Reactive/regenerative changes in AKI                                     | 4 (17.4)              | 4 (100.0) | 0 |
| Consistent with early chronic changes (tubular atrophy/interstitial fibrosis) | 11 (47.8)             | 2 (18.2) | 9 (81.8) |
| Areas with multinucleated cells                                         | 5 (21.7)              | 1 (20.0) | 4 (80.0) |
| Renal peritubular microenvironment features on PAS (cortical)           |                       |          |          |
| No changes                                                              | 10 (43.5)             | 6 (60.0) | 4 (40.0) |
| Reactive/regenerative changes in AKI                                     | 13 (56.5)             | 1 (7.7)  | 12 (92.3) |
| Renal peritubular microenvironment features on PAS (cortical)           |                       |          |          |
| No changes                                                              | 15 (65.2)             | 6 (40.0) | 9 (60.0) |
| Tubulorrhexis                                                           | 3 (13.0)              | 1 (33.3) | 2 (66.7) |
| Fragmentation/duplication of basement membrane                          | 3 (13.0)              | 0        | 3 (100)  |
| Thickened basement membrane                                             | 2 (8.7)               | 0        | 2 (100)  |

Values are presented as number (%) unless otherwise indicated.

Significant p-value < .05.

CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; AKI, acute kidney injury; ATN, acute tubular necrosis; H&E, hematoxylin and eosin; PAS, periodic acid-Schiff.
Table 2. Results of the logistic regression analysis with vimentin expression as a dependent variable (univariate analysis)

| Variable                        | Univariate analysis |   |   |
|---------------------------------|---------------------|--|--|
|                                 | OR                  | 95% CI    | p-value |
| **Age (yr)**                    |                     |   |   |
| ≤ 65                            | 1                   | -         | -       |
| > 65                            | 5.778               | 0.819–40.760 | .078   |
| **Sex**                         |                     |   |   |
| Female                          | 1                   | -         | -       |
| Male                            | 0.450               | 0.074–2.741 | .386   |
| **Cause of death**              |                     |   |   |
| Sepsis                          | 1                   | -         | -       |
| Respiratory                     | 0.800               | 0.076–8.474 | .853   |
| Cardiac                         | 1.200               | 0.073–19.631 | .898   |
| Stroke                          | 0.400               | 0.061–10.017 | .577   |
| Other                           | -                   | -         | -       |
| **CKD**                         |                     |   |   |
| No                              | 1                   | -         | -       |
| Yes                             | 3.600               | 0.345–37.616 | .285   |
| **Fold eGFR**                   |                     |   |   |
| < –0.5                          | 1                   | -         | -       |
| ≥ –0.5                          | 1.067               | 0.129–8.793 | .952   |
| **Fold creatinine**             |                     |   |   |
| < 2.0                           | 1                   | -         | -       |
| ≥ 2.0                           | 2.500               | 0.214–29.254 | .465   |
| **Diabetes mellitus**           |                     |   |   |
| No                              | 1                   | -         | -       |
| Yes                             | 3.600               | 0.345–37.616 | .285   |
| **Hypertension**                |                     |   |   |
| No                              | 1                   | -         | -       |
| Yes                             | 0.880               | 0.125–6.192 | .898   |
| **Shock during hospitalization**|                     |   |   |
| No                              | 1                   | -         | -       |
| Yes                             | 1.037               | 0.173–6.233 | .968   |
| **AKI**                         |                     |   |   |
| No                              | 1                   | -         | -       |
| Yes                             | 0.514               | 0.076–3.488 | .496   |
| **AKI type**                    |                     |   |   |
| No                              | 1                   | -         | -       |
| Prerenal                        | 0.667               | 0.084–5.301 | .702   |
| Renal                           | 0.286               | 0.023–3.523 | .328   |
| **Arteriosclerosis**            |                     |   |   |
| No                              | 1                   | -         | -       |
| Yes                             | 7.714               | 0.746–79.771 | .087   |
| **Glomerulosclerosis**          |                     |   |   |
| <10% globally sclerotic glomeruli | 1              | -         | -       |
| ≥10% globally sclerotic glomeruli | 10.000          | 0.957–104.490 | .054   |
| **Glomerulosclerosis severity (%)** |                 |   |   |
| <10                             | 1                   | -         | -       |
| 10–50                           | 1.636               | 0.138–19.387 | .696   |
| >50                             | -                   | -         | -       |
| **Significant interstitial fibrosis** |                 |   |   |
| No                              | 1                   | -         | -       |
| Yes                             | 5.778               | 0.819–40.760 | .078   |

(Continued to the next page)
In this study, we showed a significant association between VIM expression by cortical tubular epithelia and RTR in the setting of AKI/ATN. First, VIM can be expressed by cortical tubular epithelia, but never by medullary epithelia, in diverse histologic landscapes. The cortical tubular epithelium of degenerated nephrons with patchy interstitial fibrosis, glomerulosclerosis, and tubular atrophy can display widespread VIM expression. For instance, severely impaired tubules with hyaline casts, so-called tubular thyroidization, exhibited diffuse and strong positivity for VIM (Fig. 1A). This aberrant VIM expression in CKD represented an obstacle to evaluating RTR in AKI. As an attempt to explore the relationship between VIM expression and RTR, we quantify VIM immunoreactivity in areas without chronic damage or tissue remodeling (Fig. 1B). Thus, any VIM expression by the cortical tubular epithelium of preserved nephrons can be considered a response to acute injury. In fact, the most severe cases of ATN displayed widespread VIM expression in tubular epithelial cells, a finding that has been observed in animal models [29]. Although the fold changes in creatinine and eGFR correlated with histologic evidence of AKI/ATN, they were not significantly associated with VIM expression in our cohort. This might be because the autopsies were performed at different stages of AKI. In fact, we hypothesize that, in some cases, VIM expression was low because there was not enough time to develop a regenerative response in the tubules.

The VIM evaluation criteria proposed in our study are based on the number of positive tubules (defined as more than 50% of the tubular epithelial cells showing positive gold-brown cytoplasmic stain within each tubule) in an average of 30 tubules (counted randomly within 10 HPFs) and dividing this number by the total number of tubules assessed, multiplied by 100. This percentage is referred to as the VIM score. A VIM score < 3% signifies low VIM expression; a VIM score ≥ 3% signifies high VIM expression. After systematic quantification, VIM was an independent predictor for RTR with 18-fold risk. There was no statistically significant difference between patients with regard to clinical characteristics. VIM, also known as fibroblast intermediate filament, is the major intermediate filament found in stromal cells [30]. These cell types include fibroblasts, endothelial cells, macrophages,

### DISCUSSION

Table 2. Continued

| Variable                                                      | Univariate analysis |   |   |
|---------------------------------------------------------------|---------------------|--|--|
| Evidence of AKI                                               |                     |   |   |
| No                                                            | 1                   |   |   |
| Yes                                                           | 7.500               | 1.023–54.996 | .047 |
| Tubulorrhexis                                                 |                     |   |   |
| No                                                            | 1                   |   |   |
| Yes                                                           | 0.308               | 0.044–2.171 | .237 |
| Evidence of ATN                                               |                     |   |   |
| No                                                            | 1                   |   |   |
| Yes                                                           | 3.214               | 0.474–21.800 | .232 |
| Evidence of regenerating tubular epithelium                   |                     |   |   |
| No                                                            | 1                   |   |   |
| Yes                                                           | 18.000              | 1.632–198.508 | .018 |
| Microenvironment features on H&E (cortical)                   |                     |   |   |
| Reactive/再生的 in AKI                                          | 1                   |   |   |
| Areas with multinucleated cells                                | 0.889               | 0.061–12.885 | .931 |
| Consistent with chronic changes (tubular atrophy/interstitial fibrosis) | -                  | - |   |
| No changes                                                    | -                   | - |   |
| Microenvironment features on PAS (cortical)                   |                     |   |   |
| No changes                                                    | 1                   |   |   |
| Tubulorrhexis                                                 | 1.333               | 0.098–18.192 | .829 |
| Fragmentation/duplication of basement membrane                | -                   | - |   |
| Thickened basement membrane                                   | -                   | - |   |

OR, odds ratio; CI, confidence interval; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; AKI, acute kidney injury; ATN, acute tubular necrosis; H&E, hematoxylin and eosin; PAS, periodic acid-Schiff. Significant p-value < .05.

1.023 to 54.996; p = .047 and OR, 18.000; 95% CI, 1.632 to 198.508; p = .018, respectively (Table 2).

### DISCUSSION

In this study, we showed a significant association between VIM expression by cortical tubular epithelia and RTR in the setting of AKI/ATN. First, VIM can be expressed by cortical tubular epithelia, but never by medullary epithelia, in diverse histologic landscapes. The cortical tubular epithelium of degenerated nephrons with patchy interstitial fibrosis, glomerulosclerosis, and tubular atrophy can display widespread VIM expression. For instance, severely impaired tubules with hyaline casts, so-called tubular thyroidization, exhibited diffuse and strong positivity for VIM (Fig. 1A). This aberrant VIM expression in CKD represented an obstacle to evaluating RTR in AKI. As an attempt to explore the relationship between VIM expression and RTR, we quantify VIM immunoreactivity in areas without chronic damage or tissue remodeling (Fig. 1B). Thus, any VIM expression by the cortical tubular epithelium of preserved nephrons can be considered a response to acute injury. In fact, the most severe cases of ATN displayed widespread VIM expression in tubular epithelial cells, a finding that has been observed in animal models [29]. Although the fold changes in creatinine and eGFR correlated with histologic evidence of AKI/ATN, they were not significantly associated with VIM expression in our cohort. This might be because the autopsies were performed at different stages of AKI. In fact, we hypothesize that, in some cases, VIM expression was low because there was not enough time to develop a regenerative response in the tubules.

The VIM evaluation criteria proposed in our study are based on the number of positive tubules (defined as more than 50% of the tubular epithelial cells showing positive gold-brown cytoplasmic stain within each tubule) in an average of 30 tubules (counted randomly within 10 HPFs) and dividing this number by the total number of tubules assessed, multiplied by 100. This percentage is referred to as the VIM score. A VIM score < 3% signifies low VIM expression; a VIM score ≥ 3% signifies high VIM expression. After systematic quantification, VIM was an independent predictor for RTR with 18-fold risk. There was no statistically significant difference between patients with regard to clinical characteristics. VIM, also known as fibroblast intermediate filament, is the major intermediate filament found in stromal cells [30]. These cell types include fibroblasts, endothelial cells, macrophages,
melanocytes, Schwann cells, and lymphocytes [31]. This is in contrast to keratin, which is the intermediate filament found in epithelial cells. Studies have shown that undifferentiated cells of the metanephric mesenchyme express VIM but not cytokeratins [32]. Tubular epithelial cells, however, do not express VIM at any developmental stage [32]. This supports the notion that the presence of VIM-positive cells in the kidney exemplifies the mesenchymal phenotype where cells undergo EMT [33]. A study by Mezni et al. [33] demonstrated that tubular expression of VIM is a good marker of EMT and can predict long-term renal graft fibrosis.

As we mentioned earlier, there is evidence in the literature of renal tubular epithelial regeneration post-injury. A study by Vogtseder et al. [34] and another by Fujigaki et al. [19] showed that dividing cells in the S3 segment of proximal tubules and in the distal tubules had a basolateral expression of Na-K-ATPase (a marker of terminal epithelial differentiation) at the same level as neighboring non-proliferating cells. These cells survived after injury carrying intact nuclei, actively proliferating, and expressing VIM. Such cells can be referred to as progenitor cells of the kidney [35]. In 2003, Maeshima et al. identified progenitor-like cells present throughout the renal tubules of adult rats via BrdU labeling [36]. Thereafter, more studies followed, proving the existence of progenitor/stem cell-like cells in the adult kidney [37,38]. Kitamura et al. [37], for instance, isolated a cell line (rKS56) with a high proliferative potential from adult rat kidneys. Interestingly, Bussolati et al. [38] recently discovered CD133+ progenitor cells within the adult human kidney and expressing the embryonic kidney marker PAX2. Those cells were capable of expansion and self-renewal in vitro.

Several studies have described this subpopulation of cells having stem cell/progenitor properties different from those of normal epithelial cells [29,38,39]. The main markers of this population were CD24, CD133, and VIM. These progenitor cells were scattered throughout the proximal tubule in the normal human kidney [29]. Compared to conventional epithelial cells, progenitor cells contain less cytoplasm, fewer mitochondria, and have no brush border [29]. Regenerating tubular epithelium is likely a collagen of expanded progenitor cells with diverse stages of maturation/differentiation. VIM expression in regenerating tubules could be secondary to activated transitory EMT programs prior to full functional and morphologic recovery [29,40]. Reviewing the literature on RTR and nephrogenic markers of regeneration reveals some pre-clinical in vitro and in vivo studies and a few other studies conducted on humans. Hansson et al. [41] used transmission electron microscopy, immunoelectron microscopy, and immunofluorescence of the human kidney cortex to explore progenitor-like cells following injury. Regenerating tubules demonstrated expression of progenitor-cell markers such as CD133, VIM, KRT19, and CLDN1 [41]. Vanthsterdam et al. [42] showed some regenerating cells in renal tubules after ischemia and expressing BrdU, CD44, and VIM could originate from an extrarenal source and reach the renal parenchyma via blood vessels [42].

Our study demonstrates, with statistically significant evidence (p = .018), the correlation between RTR and high VIM expression. This further supports what has been previously observed in other studies regarding the validity of VIM as a potential regenerative biomarker. In our study, we found correlation between VIM expression and different features of AKI other than histologic findings such as arteriosclerosis, arteriolosclerosis, and glomerulosclerosis. The meaning of VIM expression in CKD is more ambiguous. Interestingly, VIM-expressing epithelial cells are encountered, in addition to CKD, in many other chronic diseases characterized by parenchymal loss and tissue fibrosis, such as idiopathic pulmonary fibrosis, cirrhosis, and scleroderma, among others [40,43-45]. Persistence of VIM-expressing epithelia has been associated with organ dysfunction and fibrogenesis [46]. Further studies can elucidate the role of VIM expression in CKD.

We acknowledge that our study has several limitations. First, in the case of an autopsy, searching the entire kidney specimen and performing immunohistochemistry on a whole section slide is possible, although in practice, one representative section usually is submitted and retained for a specific time period (three months after the final report for wet tissues in non-forensic autopsies, according to the College of American Pathologists recommendations for the minimum requirements for retention of laboratory records and materials [47]). Hence, it is not possible to acquire further sections from the kidney specimens. Second, since we used kidney tissues from deceased patients, autolysis can alter the reactivity to IHC assays. In a few tested autolysed tissues, VIM immunoreactivity decreases with autolytic changes. Interstitial and glomerular stromal cells served as positive internal controls. Third, due to the retrospective nature of our study, selection bias and performance bias were inevitable. Lastly, our patient cohort was selected from a single medical center and was a relatively small sample size; therefore, future studies are warranted from multiple centers to verify the results on a larger population of patients. Nevertheless, future studies would be of interest to evaluate the clinical significance of VIM expression in renal biopsies from living patients to assess adequately RTR.
Conclusion

There is a need to identify novel biomarkers for RTR. Our findings suggest that VIM could serve as an excellent potential IHC marker for RTR following AKI in the right clinical and morphologic context, especially important since regenerative responses are difficult to appreciate on routine light microscopy. Nonetheless, correlation with H&E findings remains critical to exclude chronic tubular damage. Collectively, our preliminary results pave the way for future studies of larger sample size to validate the use of VIM as a reliable biomarker for RTR.

Ethics Statement

All procedures performed in the current study were performed in accordance with the 1964 Helsinki declaration and its later amendments. Formal written informed consent and approval by the Institutional Review Board (IRB) of Mount Sinai Medical Center of Florida were not required since the included patients were deceased at the time of the study. Chart review was carried out by CITI (Collaborative Institutional Training Initiative)-certified physicians.

Availability of Data and Material

The datasets generated or analyzed during the study are available from the corresponding author on reasonable request.

Code Availability

Not applicable.

ORCID

Juan Carlos Alvarez Moreno https://orcid.org/0000-0001-7517-7044
Hisham F. Bahmad https://orcid.org/0000-0003-3799-2595
Christopher A. Febres-Aldana https://orcid.org/0000-0002-4754-1344
Andrés Pirela https://orcid.org/0000-0001-5884-4909
Andres Azuero https://orcid.org/0000-0002-4601-8383
Ali Salami https://orcid.org/0000-0003-3343-4035
Robert Poppiti https://orcid.org/0000-0003-2561-2583

Author Contributions

Conceptualization: RP. Data curation: JCAM, HFB, AP, AA. Formal analysis: AS. Investigation: JCAM, HFB, CAFA, AP, AA. Methodology: JCAM, HFB, AS. Project administration: RP, JCAM. Resources: JCAM, Software: AS. Supervision: RP. Validation: CAFA, RP. Visualization: JCAM, HFB, CAFA, RP. Writing—original draft: JCAM, HFB. Writing—review & editing: CAFA, AP, AA. Approval of final manuscript: all authors.

Conflicts of Interest

The authors declare that they have no potential conflicts of interest.

Funding Statement

No funding to declare.

References

1. Eknoyan G, Agodoa L. On improving outcomes and quality of dialysis care, and more. Am J Kidney Dis 2002; 39: 889-91.
2. Makris K, Spanou I. Acute kidney injury: definition, pathophysiology and clinical phenotypes. Clin Biochem Rev 2016; 37: 85-98.
3. Akcay A, Turkmen K, Lee D, Edelstein CL. Update on the diagnosis and management of acute kidney injury. Int J Nephrol Renovasc Dis 2010; 3: 129-40.
4. Basile DP, Anderson MD, Sutton TA. Pathophysiology of acute kidney injury. Compr Physiol 2012; 2: 1303-53.
5. Sawhney S, Fraser SD. Epidemiology of AKI: utilizing large databases to determine the burden of AKI. Adv Chronic Kidney Dis 2017; 24: 194-204.
6. Siew ED, Davenport A. The growth of acute kidney injury: a rising tide or just closer attention to detail? Kidney Int 2015; 87: 46-61.
7. Hoste EA, Kellum JA, Selby NM, et al. Global epidemiology and outcomes of acute kidney injury. Nat Rev Nephrol 2018; 14: 607-25.
8. Pugh D, Gallacher PJ, Dhaun N. Management of hypertension in chronic kidney disease. Drugs 2019; 79: 365-79.
9. Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS; Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation 2001; 104: 1985-91.
10. Rosen S, Stillman JE. Acute tubular necrosis is a syndrome of physiologic and pathologic dissociation. J Am Soc Nephrol 2008; 19: 871-5.
11. Berger K, Moeller MJ. Mechanisms of epithelial repair and regeneration after acute kidney injury. Semin Nephrol 2014; 34: 394-403.
12. Wen Y, Yang C, Menez SP, Rosenberg AZ, Parikh CR. A systematic review of clinical characteristics and histologic descriptions of acute tubular injury. Kidney Int Rep 2020; 5: 1993-2001.
13. Toback FG. Regeneration after acute tubular necrosis. Kidney Int 1992; 41: 226-46.
14. Bonventre JV. Dedifferentiation and proliferation of surviving epithelial cells in acute renal failure. J Am Soc Nephrol 2003; 14 Suppl 1: S55-61.
15. Andrianova NV, Buyan MI, Zorova LD, et al. Kidney cells regeneration: dedifferentiation of tubular epithelium, resident stem cells and possible niches for renal progenitors. Int J Mol Sci 2019; 20: 6326.
16. Solez K, Morel-Maroger L, Sraer JD. The morphology of “acute tubular necrosis” in man: analysis of 57 renal biopsies and a comparison with the glycerol model. Medicine (Baltimore) 1979; 58: 362-76.
17. Molitoris BA, Holiien CA, Dahl R, Ahnen DJ, Wilson PD, Kim J. Characterization of ischemia-induced loss of epithelial polarity. J Membr Biol 1988; 106: 233-42.
18. Witzgall R, Brown D, Schwarz C, Bonventre JV. Localization of proliferating cell nuclear antigen, vimentin, c-Fos, and clusterin in the postischemic kidney. Evidence for a heterogenous genetic response among nephron segments, and a large pool of mitotically active and dedifferentiated cells. J Clin Invest 1994; 93: 2175-88.
19. Fujigaki Y, Goto T, Sakakima M, et al. Kinetics and characterization of initially regenerating proximal tubules in S3 segment in response to various degrees of acute tubular injury. Nephrol Dial Transplant 2006; 21: 41-50.
20. Frazier KS, Seely JC, Hard GC, et al. Proliferative and nonproliferative lesions of the rat and mouse urinary system. Toxicol Pathol 2012; 40(4 Suppl): 14S-86S.
21. Schena FP. Role of growth factors in acute renal failure. Kidney Int Suppl 1998; 66: S11-5.
22. Devarajan P, Mishra J, Supavekin S, Patterson LT, Steven Potter S.
Gene expression in early ischemic renal injury: clues towards pathogenesis, biomarker discovery, and novel therapeutics. Mol Genet Metab 2003; 80: 365-76.

23. Joh K, Muso E, Shigematsu H, et al. Renal pathology of ANCA-related vasculitis: proposal for standardization of pathological diagnosis in Japan. Clin Exp Nephrol 2008; 12: 277-91.

24. Textor SC. Pathophysiology of renal artery disease. In: Creager MA, Beckman JA, Loscalzo J, eds. Vascular medicine: a companion to Braunwald's heart disease. 2nd ed. Philadelphia: W.B. Saunders, 2013; 285-95.

25. Breshears MA, Confer AW. The urinary system. In: Zachary JF, ed. Pathologic basis of veterinary disease. St. Louis: Elsevier, 2017: 617-81.

26. Mehendiratta M, Bishen KA, Boaz K, Mathias Y. Ghost cells: a journey in the dark. Dent Res J (Isfahan) 2012; 9(Suppl 1): S1-8.

27. Gonlusen G, Ergin M, Paydas S, Tunali N. The expression of cytoskeletal proteins (alpha-SMA, vimentin, desmin) in kidney tissue: a comparison of fetal, normal kidneys, and glomerulonephritis. Int Urol Nephrol 2001; 33: 299-305.

28. Inker LA, Shaffi K, Levey AS. Estimating glomerular filtration rate using the chronic kidney disease-epidemiology collaboration creatinine equation: better risk predictions. Circ Heart Fail 2012; 5: 303-6.

29. Smeets B, Boor P, Dijkman H, et al. Proximal tubular cells contain a phenotypically distinct, scattered cell population involved in tubular regeneration. J Pathol 2013; 229: 645-59.

30. Robinson-Bennett B, Han A. Role of immunohistochemistry in elucidating lung cancer metastatic to the ovary from primary ovarian carcinoma. In: Hayat MA, ed. Handbook of immunohistochemistry and in situ hybridization of human carcinomas. Amsterdam: Elsevier Academic Press, 2006; 537-45.

31. Kokkinos MI, Wafai R, Wong MK, Newgreen DF, Thompson EW, Waltham M. Vimentin and epithelial-mesenchymal transition in human breast cancer: observations in vitro and in vivo. Cells Tissues Organs 2007; 185: 191-203.

32. Holthofer H, Miettinen A, Lehto VP, Lehtonen E, Virtanen I. Expression of vimentin and cytoskeleton proteins in developing and adult human kidneys. Lab Invest 1984; 50: 552-9.

33. Mezní I, Xu-Dubois Y, Galichon P, et al. Tubular expression of vimentin as a biomarker of kidney graft fibrogenesis: invasive and noninvasive measurements: abstract# A22. Transplantation 2014; 98: 877.

34. Vogtseeder A, Karadeniz A, Kaisling B, Le Hir M. Tubular cell proliferation in the healthy rat kidney: Histochem Cell Biol 2005; 124: 97-104.

35. Chambers BE, Wingert RA. Renal progenitors: roles in kidney disease and regeneration. World J Stem Cells 2016; 8: 367-75.

36. Maeshima A, Yamashita S, Nojima Y. Identification of renal progenitor-like tubular cells that participate in the regeneration processes of the kidney. J Am Soc Nephrol 2003; 14: 3138-46.

37. Kitamura S, Yamasaki Y, Kinomura M, et al. Establishment and characterization of renal progenitor-like cells from S3 segment of nephron in rat adult kidney. FASEB J 2005; 19: 1789-97.

38. Bussolati B, Bruno S, Grange C, et al. Isolation of renal progenitor cells from adult human kidney. Am J Pathol 2005; 166: 545-55.

39. Kim K, Lee KM, Han DJ, Yu E, Cho YM. Adult stem cell-like tubular cells reside in the corticomedullary junction of the kidney. Int J Clin Exp Pathol 2008; 1: 232-41.

40. Cheaito KA, Bahmad HF, Hadadeh O, et al. EMT markers in locally-advanced prostate cancer: predicting recurrence? Front Oncol 2019; 9: 131.

41. Hansson J, Hultenby K, Cramnert C, et al. Evidence for a morphologically distinct and functionally robust cell type in the proximal tubules of human kidney. Hum Pathol 2014; 45: 382-93.

42. Vansthertem D, Caron N, Decleves AE, et al. Label-retaining cells and tubular regeneration in postischaemic kidney. Nephrol Dial Transplant 2008; 23: 3786-97.

43. Wolters PJ, Collard HR, Jones KD. Pathogenesis of idiopathic pulmonary fibrosis. Annu Rev Pathol 2014; 9: 157-79.

44. Lee SJ, Yoo JD, Choi SY, Kwon OS. The expression and secretion of vimentin in the progression of non-alcoholic steatohepatitis. BMB Rep 2014; 47: 457-62.

45. Li FJ, Surolia R, Li H, et al. Autoimmunity to vimentin is associated with outcomes of patients with idiopathic pulmonary fibrosis. J Immunol 2017; 199: 1596-605.

46. Danielsson F, Peterson MK, Caldeira Araujo H, Lautenschlager F, Gad AK. Vimentin diversity in health and disease. Cells 2018; 7: 147.

47. CAP Policy Manual: Policy PP. Minimum period of retention of laboratory records and materials. Northfield: College of American Pathologists, 2020.